Converging evidence implicates cerebral white matter changes (WMC) in the pathogenesis of late-life depression. Overall progression of WMC has been associated with cardiovascular risk factors, in particular hypertension and smoking, and in older people WMC severity is strongly associated with poorer response to treatment, development of future depressive symptoms and worse long-term outcome. Despite these findings, the direction of causation between WMC and depression remains unclear as most studies are cross-sectional; in particular, few studies have investigated the influence of WMC progression on depressive outcomes. The possibility still remains that both WMC and depressive symptoms are linked, but the directionality of this association remains unclear.

### Aims

To investigate the relationship between baseline and incident depression and progression of white matter changes.

### Method

In a longitudinal multicentre pan-European study (Leukoaraiosis and Disability in the elderly, LADIS), participants aged over 64 underwent baseline magnetic resonance imaging (MRI) and clinical assessments. Repeat scans were obtained at 3 years. Depressive outcomes were assessed in terms of depressive episodes and the Geriatric Depression Scale (GDS). Progression of WMC was measured using the modified Rotterdam Progression scale.

### Results

Progression of WMC was significantly associated with incident depression during year 3 of the study ($P = 0.002$) and remained significant after controlling for transition to disability, baseline WMC and baseline history of depression. There was no significant association between progression of WMC and GDS score, and no significant relationship between progression of WMC and history of depression at baseline.

### Conclusions

Our results support the vascular depression hypothesis and implicate WMC as causal in the pathogenesis of late-life depression.

### Declaration of interest

A.W. is a member of advisory boards for Lundbeck and AGAD-II, and has received honoraria from Pfizer, Lundbeck, Novartis and Philips. D.I. served on a scientific advisory board for Servier, and has received speaker honoraria from Bayer Schering Pharma, Novartis, Pfizer and Sanofi-Aventis. L.P. has received travel funds from Bayer Italy. J.T.O’B. has been a consultant for GE Healthcare, Servier and Bayer Healthcare and has received honoraria for talks from Pfizer, GE Healthcare, Eisai, Shire, Lundbeck, Lilly and Novartis.

### Background

Brain white matter changes (WMC) and depressive symptoms are linked, but the directionality of this association remains unclear.

### Aims

To investigate the relationship between baseline and incident depression and progression of white matter changes.

### Method

In a longitudinal multicentre pan-European study (Leukoaraiosis and Disability in the elderly, LADIS), participants aged over 64 underwent baseline magnetic resonance imaging (MRI) and clinical assessments. Repeat scans were obtained at 3 years. Depressive outcomes were assessed in terms of depressive episodes and the Geriatric Depression Scale (GDS). Progression of WMC was measured using the modified Rotterdam Progression scale.

### Results

Progression of WMC was significantly associated with incident depression during year 3 of the study ($P = 0.002$) and remained significant after controlling for transition to disability, baseline WMC and baseline history of depression. There was no significant association between progression of WMC and GDS score, and no significant relationship between progression of WMC and history of depression at baseline.

### Conclusions

Our results support the vascular depression hypothesis and implicate WMC as causal in the pathogenesis of late-life depression.

### Declaration of interest

A.W. is a member of advisory boards for Lundbeck and AGAD-II, and has received honoraria from Pfizer, Lundbeck, Novartis and Philips. D.I. served on a scientific advisory board for Servier, and has received speaker honoraria from Bayer Schering Pharma, Novartis, Pfizer and Sanofi-Aventis. L.P. has received travel funds from Bayer Italy. J.T.O’B. has been a consultant for GE Healthcare, Servier and Bayer Healthcare and has received honoraria for talks from Pfizer, GE Healthcare, Eisai, Shire, Lundbeck, Lilly and Novartis.
Most participants (of age-related WMC on MRI scan, according to the Fazekas scale) were identified at neurology/psychiatry clinics, and were discovered to have WMC during their investigation. The remainder were volunteers from other studies, or those with incidental findings of WMC on MRI or computed tomography. Participants were excluded if they had: (a) the presence of severe physical illnesses; (b) severe unrelated neurological diseases; (c) leukoencephalopathies revealed by brain imaging that turned out to be of non-vascular origin; or (d) severe psychiatric disorders. All procedures were explained to participants who gave written consent to participate.

As part of the study, all participants had a baseline MRI scan at their respective centres. The study design was to repeat MRI on all participants after 3 years. However, MRI scans were not repeated at one centre (n=60) due to logistical constraints, leaving 579 possible participants in the study. Repeat magnetic resonance data were obtained from 394 individuals. Of the remaining 185, 38 had died, 63 had dropped out of the LADIS study altogether, 5 had unsatisfactory or missing baseline scans and 79 LADIS participants refused or were not available for a second scan. The mean interval between scans was 3.12 years (s.d.=0.33).

MRI acquisition

All centres used MRI systems with a field strength of 1.5 T, apart from one centre that had a 0.5 T system. The standard protocol used for baseline scans was repeated. For the white matter rating, a FLAIR (fluid attenuated inversion recovery) sequence was acquired with the following parameters: field of view (FOV) = 250 mm, 256 × 256 or 256 × 192 matrix, 5 mm slice thickness, 0.5 mm slice gap, 19–28 slices, echo time (TE) = 100–140 ms, repetition time (TR) = 6000–10000 ms, inversion time (TI) = 2000–2500 ms, echoes per shot 7–24. Volumetric analysis was performed by a single rater in Amsterdam on a Sparc 5 workstation on Unix (SUN, Palo Alto, California, USA). No distinction was made between subcortical and periventricular WMC. Areas of WMC around infarcts and lacunes were disregarded. Further details of the quantification process are described elsewhere.

Progression of WMC was measured at one centre (Amsterdam) using the modified Rotterdam Progression scale (absence/presence of progression in nine brain regions). Areas of WMC around infarcts and lacunes were disregarded. We used the total sum of changes in all regions in order to increase sensitivity – previous research has shown that cardiovascular risk factors are associated with progression of total WMC.

Assessment of depressive outcomes

Depressive symptoms were assessed by the self-completed 15-item Geriatric Depression Scale (GDS). The GDS is a self-reported questionnaire specifically developed as a screening instrument for the presence of depressive symptoms in older populations. Depressive symptoms were assessed at baseline as well as at 3 years. A history of treatment for depression was recorded at baseline, along with the date of any incident depression over the follow-up period. History of depression was defined as a past medical history for a depressive episode requiring treatment (i.e. prescription of antidepressant medication, psychotherapy, electroconvulsive therapy) or hospital admission. Incident depression at each yearly visit was similarly defined as any depressive episode requiring treatment or hospital admission in the year preceding the visit. Our primary outcome variable was a depressive episode in the year preceding the third follow-up visit. Both history and incident depression were obtained through a combination of participant interview and evaluation of the case notes.

Assessment of potential mediators or confounders

All participants had a comprehensive baseline demographic and clinical assessment administered by trained personnel. Information was collected on age, gender, education, occupational status, living conditions and previous medical conditions. Current smoking status, alcohol intake and physical activity (defined as at least 30 min of physical activity on at least 3 days per week) were also recorded. Functional status in terms of disability was measured by means of the IADL scale. This is a scale developed to monitor function and independent living among older adults and measures a broad set of daily activities including shopping for personal items, preparing meals, performing housework and managing personal finances. The Mini-Mental State Examination (MMSE) was used to assess cognition. To increase reliability, investigators were issued with a specifically designed handbook that contained guidelines for applying tools. A test of the interrater, intercentre reliability of IADL scoring showed good agreement in ratings of each scale item (K statistic ranging from 0.69 to 0.85). Participants were re-evaluated on all scales at 1, 2 and 3 years. Transition to disability was defined as the change from none or one to at least two impaired IADL items.

Statistical analysis

Data were collected in each centre and entered into a central electronic database on a specifically developed website (www.unifi.it/LADIS). As GDS, MMSE, WMC and progression of WMC were not normally distributed, we used non-parametric statistics – Spearman correlation coefficient and Mann–Whitney tests for the initial analysis. Binary categorical variables were analysed using Fisher's exact test. A binary logistic regression model was used to examine further the relationship between progression of WMC and depression at 3 years with covariates of possible confounding variables of age, gender, baseline WMC, MMSE, transition to disability, baseline depression and study centre. The significance level was set at P<0.05.

Results

Magnetic resonance repeat data were obtained from 394 participants. Table 1 shows the characteristics of participants with v. without repeat imaging. Those with imaging were on average 2 years younger, had a smaller volume of WMC, higher MMSE and lower GDS scores. The GDS score did not change on average over the 3 years in either group.

Those who had a stroke during the study period had a higher GDS score at 3 years compared with those who did not (4.7 (s.d.=3.3) vs. 3.0 (s.d.=2.9), Mann–Whitney Z=−3.0, P=0.002). There was, however, no difference in depression incidence at 3 years (7/33 v. 40/355, Fisher P=0.10) or over the 3-year study duration (11/31 v. 78/336, Fisher P=0.13). There was no significant difference in MMSE decline between those with depression at 3 years (change MMSE=−1.3 (s.d.=3.9))
compared with those without depression (change MMSE = −0.82 (s.d. = 2.9)).

As Fig. 1 illustrates, progression of WMC was greater in those with v. without a depressive episode during year 3 (Mann–Whitney Z = 3.1, P = 0.002; progression of WMC median 2 (IQR = 1:4) v. 1 (IQR = 0:3)). Progression of WMC was also greater in those with (2 (IQR = 1:3) v. without (1 (IQR = 0:3)) a depressive episode during years 1, 2 and 3 (Mann–Whitney Z = −2.8, P = 0.006). There were no significant differences in progression of WMC between those with v. without baseline history of depression (Z = 0.11, P = 0.9; median 2 (IQR = 0:3) v. 2 (IQR = 0:3)).

Table 2 shows univariate correlates of the WMC progression. Greater progression of WMC was associated with greater baseline WMC, age at baseline, decline in MMSE and lower MMSE at 3 years but not baseline. There were no significant correlations between progression of WMC and GDS score at baseline or 3 years. Transition to disability over the 3 years was significantly greater (Fisher’s exact test, P = 0.008) in those reporting a depressive episode during year 3 (21/47) v. those not reporting depression (86/341).

Table 3 shows the results of a multivariate binary logistic regression of depressive episode during year 3 with variables of age, gender, body mass index, baseline smoking and alcohol status, study centre, baseline MMSE, change in MMSE, incident stroke, baseline WMC volume, baseline history of depression, transition to disability during the study period and progression of WMC. This found that significant predictors of depression at 3 years were baseline history of depression, progression of WMC, baseline alcohol intake and transition to disability.

Table 4 shows the results of a multivariate binary logistic regression with depressive incident during years 1–3, with the same covariates. In this model, significant predictors of depressive incident were history of depression, transition to disability, baseline alcohol intake and study centre.

Discussion

Main findings

The key finding from this study was that progression of WMC over 3 years predicted incidence of depression at 3 years, even after controlling for baseline WMC, previous history of depression and transition to disability over the 3 years. The data are in line with previous cross-sectional studies showing increased load of WMC in late-onset depression that vascular disease changes to the brain predispose individuals to the development of depression by disrupting fibre tracts. Although incident depression over all 3 years was associated in a univariate fashion with WMC progression, it was not significant in the multivariate model. This suggests that progression of WMC over the 3 years was more strongly associated with depression at 3 years than during the 3-year period, and fits with our hypothesis that the WMC preceded the depression.

Importantly, we did not find an association between baseline depression and longitudinal increase in WMC. This is in keeping with the findings of the PROSPER study and with cross-sectional studies that found no increase in WMC in older participants with early-onset depression. Hence, our findings suggest that WMC cause late-life depression rather than vice versa. However, our results are in contrast to those of 3C-Dijon study that reported a relationship between baseline depression and
### Table 2: Univariate correlations of progression of white matter changes

<table>
<thead>
<tr>
<th>Variable</th>
<th>n</th>
<th>Spearman, rho</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at baseline</td>
<td>394</td>
<td>0.12</td>
<td>0.019</td>
</tr>
<tr>
<td>Gender</td>
<td>394</td>
<td>−0.05</td>
<td>0.34</td>
</tr>
<tr>
<td>White matter changes, volume</td>
<td>387</td>
<td>0.48</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Baseline Mini-Mental State Examination</td>
<td>394</td>
<td>0.01</td>
<td>0.84</td>
</tr>
<tr>
<td>Baseline Geriatric Depression Scale</td>
<td>394</td>
<td>0.05</td>
<td>0.37</td>
</tr>
<tr>
<td>3-year Mini-Mental State Examination</td>
<td>385</td>
<td>−0.12</td>
<td>0.015</td>
</tr>
<tr>
<td>3-year Geriatric Depression Scale</td>
<td>387</td>
<td>0.06</td>
<td>0.26</td>
</tr>
<tr>
<td>3-year change in Geriatric Depression Scale</td>
<td>387</td>
<td>0.02</td>
<td>0.77</td>
</tr>
<tr>
<td>3-year change in Mini-Mental State Examination</td>
<td>385</td>
<td>−0.17</td>
<td>0.001</td>
</tr>
<tr>
<td>Body mass index</td>
<td>394</td>
<td>−0.04</td>
<td>0.38</td>
</tr>
<tr>
<td>Smoker at baseline</td>
<td>394</td>
<td>0.09</td>
<td>0.08</td>
</tr>
<tr>
<td>Alcohol at baseline, g/day</td>
<td>205</td>
<td>0.09</td>
<td>0.21</td>
</tr>
<tr>
<td>Physical activity at baseline, yes/no</td>
<td>394</td>
<td>0.00</td>
<td>0.96</td>
</tr>
</tbody>
</table>

### Table 3: Binary logistic regression of depressive episode during year 3 (n = 23/198)

<table>
<thead>
<tr>
<th>Wald</th>
<th>P</th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>1.03</td>
<td>0.31</td>
</tr>
<tr>
<td>Female</td>
<td>0.01</td>
<td>0.94</td>
</tr>
<tr>
<td>Baseline WMC, volume</td>
<td>0.28</td>
<td>0.60</td>
</tr>
<tr>
<td>Transition to disability</td>
<td>6.42</td>
<td>0.011</td>
</tr>
<tr>
<td>History of depression at baseline</td>
<td>6.88</td>
<td>0.009</td>
</tr>
<tr>
<td>incident stroke</td>
<td>2.70</td>
<td>0.10</td>
</tr>
<tr>
<td>MMSE baseline</td>
<td>1.03</td>
<td>0.31</td>
</tr>
<tr>
<td>3-year change in MMSE</td>
<td>0.01</td>
<td>0.92</td>
</tr>
<tr>
<td>Body mass index baseline</td>
<td>0.01</td>
<td>0.91</td>
</tr>
<tr>
<td>Physical activity</td>
<td>0.03</td>
<td>0.87</td>
</tr>
<tr>
<td>Smoking baseline</td>
<td>2.89</td>
<td>0.089</td>
</tr>
<tr>
<td>Alcohol baseline, g/day</td>
<td>5.99</td>
<td>0.014</td>
</tr>
<tr>
<td>Progression of WMC a</td>
<td>3.90</td>
<td>0.048</td>
</tr>
<tr>
<td>Study centre</td>
<td>11.69</td>
<td>0.23</td>
</tr>
</tbody>
</table>

WMC, white matter changes; MMSE, Mini-Mental State Examination.

### Table 4: Binary logistic regression of depressive episode during year 1+2+3 (n = 41/188)

<table>
<thead>
<tr>
<th>Wald</th>
<th>P</th>
<th>Hazard ratio (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>0.71</td>
<td>0.40</td>
</tr>
<tr>
<td>Female</td>
<td>0.04</td>
<td>0.84</td>
</tr>
<tr>
<td>Baseline WMC, volume</td>
<td>0.22</td>
<td>0.64</td>
</tr>
<tr>
<td>Transition to disability</td>
<td>6.47</td>
<td>0.011</td>
</tr>
<tr>
<td>History of depression at baseline</td>
<td>14.58</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>incident stroke</td>
<td>0.26</td>
<td>0.61</td>
</tr>
<tr>
<td>MMSE baseline</td>
<td>0.96</td>
<td>0.33</td>
</tr>
<tr>
<td>3-year change in MMSE</td>
<td>0.26</td>
<td>0.61</td>
</tr>
<tr>
<td>Body mass index baseline</td>
<td>1.01</td>
<td>0.31</td>
</tr>
<tr>
<td>Physical activity</td>
<td>0.09</td>
<td>0.77</td>
</tr>
<tr>
<td>Smoking baseline</td>
<td>0.84</td>
<td>0.36</td>
</tr>
<tr>
<td>Alcohol baseline, g/day</td>
<td>4.73</td>
<td>0.030</td>
</tr>
<tr>
<td>Progression of WMC a</td>
<td>0.00</td>
<td>0.97</td>
</tr>
<tr>
<td>Study centre</td>
<td>20.09</td>
<td>0.017</td>
</tr>
</tbody>
</table>

WMC, white matter changes; MMSE, Mini-Mental State Examination.

---

a. Progression of WMC using the Rotterdam Progression scale.
WMC progression. The demographics of the study populations may underlie the differences. Unlike the electoral roll-based Dijon study, our study was of non-disabled community dwellers who were selected as they already had WMC. In keeping with other studies,26 we found baseline WMC a strong predictor of WMC progression. Hence pre-existing vascular disease is likely to be a major cause of WMC progression in our study.

Our findings of progression of WMC predicting future episodes of depression are contrary to the longitudinal PROSPER study.14 Again, the discrepancy may be due to differences in the cohorts studied. The PROSPER study had much lower WMC load (2 ml v. our 15 ml) and had lower incidence of depression, and hence the WMC burden may not have been sufficient to detect an increase in the incidence of depressive features. Our results are, however, in line with a study of older participants with depression at baseline,11 in which poorer outcome of depression was associated with progression of WMC, but not baseline levels of WMC.

We did not find a relationship between WMC progression and depressive symptoms as measured by the self-reported GDS. Since our definition of incident depression was that the participant received treatment, it is possible that effective treatment for depressive symptoms may have reduced GDS scores when they were recorded. Alternatively, those with worse depressive symptoms at the time of follow-up may have been more likely to decline participation.

There was a significant effect of study centre on depression over 3 years. Since the centres were heterogeneous in terms of their clinical focus (neurology, psychiatry, stroke clinics, etc.) and also culturally due to the pan-European nature of the LADIS study, it seems possible that this effect was as a result of the differing nature of the recruited population at each centre. Alcohol use at baseline was associated with depressive incidents during the study. The associations between alcohol and depression are bidirectional, with alcohol often being used by people with depression, but also leading to the development of depression.27

We have demonstrated a significant association between progression of WMC over 3 years, and depression at 3 years, controlling for a number of confounding variables. However, it is difficult to unambiguously identify a direct causal relationship between WMC and depression, because of the interlinking relationships between cardiovascular disease, disability, cognitive problems and depression. For example there are established associations between WMC and both cognitive decline28 and reduced daily physical functioning,29 and both of these in turn have links to depressive features.

Strengths and limitations

Limitations of the study are the use of a rating scale to assess WMC progression, rather than volumetric analysis, although the Rotterdam Progression scale has been widely used and is reliable and sensitive to change.30 We chose to use this scale for measuring progression, since we were not aware of any volumetric methods that had been validated in a multicentre setting, and we were concerned that the volumetric measurement might be too dependent on the MRI sequence used at the different locations. There was some participant attrition over the study period that may have affected the results, but our attrition rate is not uncommon for studies of this size and duration in older people. Arguably, those who developed depression would have been more likely to drop out, and thus if anything, the attrition rate possibly tended to reduce the significance of our findings.

Our measurement of incident depression was a depressive episode that had resulted in treatment or admission to hospital. Thus, we may have missed some cases in which the participant did not seek treatment for their illness. There may also have been lack of specificity in the diagnosis, as we did not use a standard procedure for depression (for example DSM-IV31). However, the advantage of our approach is that it should capture incidents of depression occurring at any point over the study period, rather than just at the time of assessment.

The strengths of the study are the large, multicentre, pan-European design and the size of the population, all of which increase the generalisability of the findings. We used a standardised imaging protocol, and obtained repeat imaging using the same protocol at 3 years. Analysis of scans was centralised and undertaken masked to all clinical outcome data. Unlike other studies, our comprehensive assessment package allowed us to investigate key potential confounds, such as the development of disability and cognitive impairment, which might possibly mediate the relationship between progression of WMC and future depression.

Implications

In conclusion, we found evidence that progression of WMC is associated with incidence of depression, even when controlling for other factors. Our previous reports have found an association between WMC at baseline and future depression, and we found no evidence of the reverse association between depression at baseline and future progression of WMC. Our results therefore support the vascular hypothesis of depression and are consistent with WMC pre-dating and playing a key aetiological role in the development of depression in older people. Trials of antihypertensive drugs have demonstrated that successful blood pressure control reduces progression of WMC.32,33 Reducing white matter lesion progression by means of control of vascular risk factors should thus be investigated as a potentially important strategy in treating older people with, or at risk of, depression.

Michael J. Firbank, PhD, Andrew Teodorczuk, MRCPsych, Institute for Ageing and Health, Newcastle University, Newcastle, UK; Wijsie M. van der Flier, PhD, Alida A. Gouw, MD, Department of Radiology and Neurology, VU Medical Center, Amsterdam, The Netherlands; Anders Wallin, MD, PhD, Institute of Clinical Neuroscience, Göteborg University, Göteborg, Sweden; Timo Erkinjuntti, MD, PhD, Memory Research Unit, Department of Clinical Neurosciences, Helsinki University, Helsinki, Finland; Domenico Inzitari, MD, Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy; Lars-Olof Wahlund, MD, PhD, Karolinska Institutet, Department of Neurobiology, Care Sciences and Society and Karolinska University Hospital, Huddinge, Sweden; Leonardo Pantoni, MD, PhD, Anna Poggesi, MD, Giovanni Pracucci, MD, Department of Neurological and Psychiatric Sciences, University of Florence, Florence, Italy; Peter Langhorne, MD, BSC, PhD, FRCp, John T. O’Brien, DM, Institute for Ageing and Health, Newcastle University, Newcastle, UK

Correspondence: Michael Firbank, PhD, Institute for Ageing and Health, Newcastle University Wolfson Research Centre, Campus for Ageing and Vitality, Newcastle upon Tyne NE4 5SP, UK; Email: michael.firbank@ncl.ac.uk

First received 1 Jul 2011, final revision 6 Feb 2012, accepted 15 Mar 2012

Funding

The LADIS study is supported by the European Union within the V European Framework Programme “Quality of life and management of living resources” (1999-2002), contract no: QLRT-2000-00446 as a concerted action. This work was supported by the UK NIHR Biomedical Research Centre for Ageing and Age Related Diseases award to the Newcastle upon Tyne Hospitals NHS Foundation Trust.

Acknowledgements

A list of participating centres and personnel can be found in the online supplement.
References


Online Supplement

List of participating centres and personnel.

**Helsinki, Finland** (Memory Research Unit, Department of Clinical Neurosciences, Helsinki University): Timo Erkinjuntti, MD, PhD, Tarja Pohjasvaara, MD, PhD, Pia Pihanen, MD, Raija Ylikoski, PhD, Hanna Jokinen, PhD, Meija-Marjut Somerkoski, MPsyCh, Riitta Mäntylä, MD, PhD, Olli Salonen, MD, PhD; **Graz, Austria** (Department of Neurology and Department of Radiology, Division of Neuroradiology, Medical University Graz): Franz Fazekas, MD, Reinhold Schmidt, MD, Stefan Ropele, PhD, Brigitte Rous, MD, Katja Petrovic, MagPsyChol, Ulrike Garmehi, Alexandra Seewann, MD; **Lisboa, Portugal** (Serviço de Neurologia, Centro de Estudos Egas Moniz, Hospital de Santa Maria): José M. Ferro, MD, PhD, Ana Verdelho, MD, Sofia Madureira, PsyD, Carla Moleiro, PhD; **Amsterdam, The Netherlands** (Department of Radiology and Neurology, VU Medical Center): Philip Scheltens, MD, PhD, Ilse van Straaten, MD, Frederik Barkhof, MD, PhD, Alida Gouw, MD, Wiesje van der Flier, PhD; **Goteborg, Sweden** (Institute of Clinical Neuroscience, Goteborg University): Anders Wallin, MD, PhD, Michael Jonsson, MD, Karin Lind, MD, Arto Nordlund, PsyD, Sindre Rolstad, PsyD, Ingela Isblad, RN; **Huddinge, Sweden** (Karolinska Institutet, Department of Neurobiology, Care Sciences and Society; Karolinska University Hospital Huddinge): Lars-Olof Wahlund, MD, PhD, Milita Crisby, MD, PhD, Anna Pettersson, RPT, PhD, Kaarina Amberla, PsyD; **Paris, France** (Department of Neurology, Hopital Lariboisiere): Hugues Chabriat, MD, PhD, Karen Hernandez, psychologist, Annie Kurtz, psychologist, Dominique Hervé, MD, Sarah Benisty, MD, Jean Pierre Guichard, MD; **Mannheim, Germany** (Department of Neurology, University of Heidelberg, Klinikum Mannheim): Michael Hennerici, MD, Christian Blahak, MD, Hansjorg Baezner, MD, Martin Wiarda, PsyD, Susanne Seip, RN; **Copenhagen, Denmark** (Memory Disorders Research Group, Department of Neurology, Rigshospitalet, and the Danish Research Center for Magnetic Resonance, Hvidovre Hospital, Copenhagen University Hospitals): Gunhild Waldemar, MD, DMSc, Egill Rostrup, MD, MSc; Charlotte Ryberg, MSc, Tim Dyrby MSc, Olaf B. Paulson, MD, DMSc; Ellen Garde, MD, PhD; **Newcastle-upon-Tyne, UK** (Institute for Ageing and Health, Newcastle University): John O’Brien, DM, Sanjeeet Pakrasi, MRCPsych, Mani Krishnan MRCPsych, Andrew Teodorczuk, MRCPsych, Michael Firbank, PhD, Philip English, DCR, Thais Minett, MD, PhD.

The Coordinating centre is in **Florence, Italy** (Department of Neurological and Psychiatric Sciences, University of Florence): Domenico Inzitari, MD (Study Coordinator); Luciano Bartolini, PhD, Anna Maria Basile, MD, PhD, Eliana Magnani, MD, Monica Martini, MD, Mario Mascalchi, MD, PhD, Marco Moretti, MD, Leonardo Pantoni, MD, PhD, Anna Poggesi, MD, Giovanni Pracucci, MD, Emilia Salvadori, PhD, Michela Simoni, MD.

The **LADIS Steering Committee** is formed by Domenico Inzitari, MD (study coordinator), Timo Erkinjuntti, MD, PhD, Philip Scheltens, MD, PhD, Marieke Visser, MD, PhD, and Peter Langhorne, MD, BSC, PhD, FRCP who replaced in this role Kjell Asplund, MD, PhD beginning in 2005.
Relationship between progression of brain white matter changes and late-life depression: 3-year results from the LADIS study
Michael J. Firbank, Andrew Teodorczuk, Wiesje M. van der Flier, Alida A. Gouw, Anders Wallin, Timo Erkinjuntti, Domenico Inzitari, Lars-Olof Wahlund, Leonardo Piantoni, Anna Poggesi, Giovanni Pracucci, Peter Langhorne, John T. O'Brien and the LADIS group
BJP 2012; 201:40-45.
Access the most recent version at DOI: 10.1192/bjp.bp.111.098897

Supplementary Material
Supplementary material can be found at:
http://bjp.rcpsych.org/content/suppl/2012/05/21/bjp.bp.111.098897.DC1

References
This article cites 32 articles, 11 of which you can access for free at:
http://bjp.rcpsych.org/content/201/1/40#BIBL

Reprints/permissions
To obtain reprints or permission to reproduce material from this paper, please write to permissions@rcpsych.ac.uk

You can respond to this article at
http://bjprcpsych;201/1/40

Downloaded from
http://bjp.rcpsych.org/ on June 27, 2017
Published by The Royal College of Psychiatrists

To subscribe to The British Journal of Psychiatry go to:
http://bjp.rcpsych.org/site/subscriptions/